Fundraising Fox
Lungpacer Medical
Exton, US · Founded 2009 · 58 employees on LinkedIn · 2 known investors
Find your way into Lungpacer Medical
Sign up to see every warm intro you have to Lungpacer Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lungpacer Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lungpacer Medical develops neurostimulation technologies for critical care, focused on ventilator weaning to improve outcomes for patients. Its offerings are built by a team of clinical and engineering experts.
Founders & leadership
VT
Viral ThakkarChief Operating OfficerViral Thakkar has over 20 years of experience in medical device development and manufacturing, with background in leadership roles across product development, manufacturing operations, R&D, and quality functions. He is COO of Lungpacer Medical, which develops neurostimulation technologies for critical care applications.
RD
Rosemarie DhavaleChief Financial Officer & VP of Human Resources2023–2026She brings over 25 years of financial and operational experience in the medical device and insurance industries, with expertise in corporate finance, fundraising, business valuation, and commercialization strategy across public and private organizations.
DE
Doug EvansPresident and CEODoug Evans is President and CEO of Lungpacer Medical, which develops neurostimulation technologies for ventilator weaning in critical care. He previously served as Chief Operating Officer of Kensey Nash Corporation (acquired by Royal DSM for $360M) and held board positions at TELABio (NASDAQ: TELA), WhiteSwell Medical, and Intact Vascular (acquired by Philips Medical for $360M in 2020).
Board
JP
Jan PensaertBoard director
BD
Bob DonohueBoard director
GD
Guillaume DarnandBoard director
CK
Christopher KipleChair of the Board
JW
Joseph W. KaufmannBoard director
ML
Michael L. FavetBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$137.4M disclosed across 6 rounds · 2017–2026
▶$16MraisedJul 2026 · 2 investors · Other Health CareRule 506(b)
▶$16MraisedJul 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Douglas G. EvansExecutive Officer, Director
- Joseph W. KaufmannDirector
- Bob DonohueDirector
- Christopher KipleExecutive Officer
- Jan PensaertDirector
- Jonathan ConlinExecutive Officer
- Steven E. PfanstielExecutive Officer
- Viral ThakkarExecutive Officer
- Offering amount
- $20M
- Amount sold
- $16M
- First sale
- Apr 2026
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$10MraisedApr 2025 · 2 investors · Other Health CareRule 506(b)
▶$10MraisedApr 2025 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jan PensaertDirector
- Jonathan ConlinExecutive Officer
- Bob DonohueDirector
- Douglas G. EvansExecutive Officer, Director
- Viral ThakkarExecutive Officer
- Rosemarie DhavaleExecutive Officer
- Christopher KipleExecutive Officer, Director
- Joseph W. KaufmannDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2025
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$16MraisedDec 2022 · 3 investors · Other Health CareRule 506(b)
▶$16MraisedDec 2022 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph KaufmannDirector
- Josh MakowerDirector
- Jose Calle GordoDirector
- Karen LongDirector
- Christopher KipleExecutive Officer, Director
- Douglas G. EvansExecutive Officer, Director
- Jonathan ConlinExecutive Officer
- Bob DonohueDirector
- Nawzer MehtaExecutive Officer
- Rosemarie DhavaleExecutive Officer
- Offering amount
- $21.1M
- Amount sold
- $16M
- First sale
- Dec 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$20MraisedApr 2022 · 4 investors · Other Health CareRule 506(b)
▶$20MraisedApr 2022 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Josh MakowerDirector
- Chris KipleExecutive Officer, Director
- Valeska SchroederDirector
- Rosemarie DhavaleExecutive Officer
- Lesley FronioExecutive Officer
- Douglas G. EvansExecutive Officer, Director
- Jonathan ConlinExecutive Officer
- Joseph W. KaufmannDirector
- Bob DonohueDirector
- Jose Calle GordoDirector
- Nawzer MehtaExecutive Officer
- Offering amount
- $30M
- Amount sold
- $20M
- First sale
- Apr 2022
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$55.8MraisedMay 2019 · 8 investors · Other Health CareRule 506(b)
▶$55.8MraisedMay 2019 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan ConlinExecutive Officer
- Josh MakowerDirector
- Guillaume DarnandDirector
- Michael FavetDirector
- Joseph W. KaufmannDirector
- Douglas EvansExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $55.8M
- First sale
- Apr 2019
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$19.6MraisedJun 2017 · 15 investors · Other Health CareRule 506(b)
▶$19.6MraisedJun 2017 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Douglas EvansExecutive Officer, Director
- Shannon KaustinenExecutive Officer, Director
- Michael L. FavetDirector
- Guillaume DarnandDirector
- Offering amount
- $19.6M
- Amount sold
- $19.6M
- Proceeds to insiders
- $173.5K
- First sale
- May 2017
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Synapse Biomedical Inc.Synapse Biomedical develops and commercializes neurostimulation medical devices, including the NeuRx Diaphragm Pacing System (DPS), which uses electrical stimulation of the diaphragm to treat chronic respiratory insufficiency in patients with spinal cord injuries and ALS. The company serves clinicians and patients dependent on mechanical ventilation.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies working in the same space as Lungpacer Medical.
In the news
Frequently asked questions
- What does Lungpacer Medical do?
- Lungpacer Medical develops neurostimulation technologies for critical care, focused on ventilator weaning to improve outcomes for patients. Its offerings are built by a team of clinical and engineering experts.
- Who are Lungpacer Medical's investors?
- Lungpacer Medical's investors include Keiretsu Forum, New Enterprise Associates (NEA).
- How much funding has Lungpacer Medical raised?
- Lungpacer Medical has disclosed $137.4M raised across 6 rounds.
- Where is Lungpacer Medical headquartered?
- Lungpacer Medical is headquartered in Exton, US.